Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Home-Run who wrote (1910)	5/1/1998 1:25:00 PM
From: B.REVERE	Read Replies (2) \| Respond to of 9523

[SMITH-barney upgrade]-- Viagra sales seen zooming despite insurer curbs 05/01 12:53 SALOMON SMITH BARNEY SAYS RAISES PFIZER <PFE.N> TARGET PRICE, 1999 EPS VIEW NEW YORK, May 1 (Reuters) - Salomon Smith Barney said it raised its 1999 earnings estimate and its target price for Pfizer Inc. in the wake of the success of the company's new Viagra impotence drug. -- "Viagra is not just a drug, it's a phenomenon," Salomon Smith Barney said in a research note. -- The price target was raised to $155 (previous target not provided). -- The 1999 earnings estimate went to $2.70 per share from $2.50, "but it could be as high as $3.00